Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 5807346, 9 pages
Review Article

Combining Whole-Brain Radiotherapy with Gefitinib/Erlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis

1Department of Neurosurgery, First Clinical Medical College of Lanzhou University, Lanzhou 730000, China
2Evidence-Based Medicine Center of Lanzhou University, Lanzhou 730000, China
3Key Laboratory of Evidence-Based Medicine and Knowledge Translation of Gansu Province, Lanzhou 730000, China
4Department of Neurosurgery, Affiliated Hospital, Medical College of Chinese People’s Armed Police, Tianjin 300162, China

Received 3 July 2015; Accepted 2 December 2015

Academic Editor: Jun Deng

Copyright © 2016 Mao-hua Zheng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. To comprehensively assess the efficacy and safety of whole-brain radiotherapy (WBRT) combined with gefitinib/erlotinib for treatment of brain metastases (BM) from non-small-cell lung cancer (NSCLC). Methods. Databases including PubMed,, Web of Science, and Cochrane Library were searched from inception to April 12, 2015. Studies on randomized controlled trials (RCTs) and case-control trials comparing WBRT combined with gefitinib/erlotinib versus WBRT alone for BM from NSCLC were included. Literature selection, data extraction, and quality assessment were performed independently by two trained reviewers. RevMan 5.3 software was used to analyze data. Results. A total of 7 trials involving 622 patients were included. Compared with WBRT alone or WBRT plus chemotherapy, WBRT plus gefitinib/erlotinib could significantly improve response rate (OR = 2.16, 95% CI: 1.35–3.47; ), remission rate of central nervous system (OR = 6.06, 95% CI: 2.57–14.29; ), disease control rate (OR = 3.34, 95% CI: 1.84–6.07; ), overall survival (HR = 0.72, 95% CI: 0.58–0.89; ), and 1-year survival rate (OR = 2.43, 95% CI: 1.51–3.91; ). In adverse events (III-IV), statistically significant differences were not found, except for rash (OR = 7.96, 95% CI: 2.02–31.34; ) and myelosuppression (OR = 0.19, 95% CI: 0.07–0.51; ). Conclusions. WBRT plus gefitinib/erlotinib was superior to WBRT alone and well tolerated in patients with BM from NSCLC.